|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Hepatitis C: Treatment of difficult to treat patients显示文摘Over the past several years, more so recently, treatment options for hepatitis C virus(HCV) have seemed to exponentially grow. Up until recently, the regimen of pegylated interferon(peg-IFN) and ribavirin(RBV) stood as the standard of care. Direct acting antivirals, which target nonstructural proteins involved in replication and infection of HCV were first approved in 2011 as an addition to the peg-IFN and RBV regimen and with them have come increased sustained virological response rates(SVR). The previously reported 50%-70% SVR rates using the combination of peg-IFN and RBV are no longer the standard of care with direct acting antiviral(DAA) based regimens now achieving SVR of 70%-90%. PegIFN free as well as 'all oral' regimens are also available. The current randomized controlled trials available show favorable SVRs in patients who are naive to treatment, non-cirrhotic, and not human immunodeficiency virus(HIV)-co-infected. What about patients who do not fit into these categories? In this review, we aim to discuss the currently approved and soon to be approved DAAs while focusing on their roles in patients that are treatment experienced, cirrhotic, or co-infected with HIV. In this discussion, review of the clinical trials leading to recent consensus guidelines as well as discussion of barriers to treatment will occur. A case will attempt will be made that social services, including financial support and drug/alcohol treatment, should be provided to all HCV infected patients to improve chances of cure and thus prevention of late stage sequela. | Eric G Hilgenfeldt Alex Schlachterman Roberto J Firpi | 2015 | World Journal of Hepatology2015，7，15： | 3 |
| 2 | Hepatitis C cirrhosis: New perspectives for diagnosis and treatment显示文摘Chronic hepatitis C infection is the leading cause of chronic liver disease, cirrhosis, hepatocellular carcinoma as well as the primary indication for liver transplantation in the United States. Despite recent advances in drugs for the treatment of hepatitis C, predictive models estimate the incidence of cirrhosis due to hepatitis C infection will to continue to rise for the next two decades. There is currently an immense interest in the treatment of patients with fibrosis and early-stage cirrhosis as treatment can lead to decrease in the rates of decompensated cirrhosis, hepatocellular carcinoma and need for liver transplantation in these patients. The goal of this paper is to provide clinicians and health care professionals further information about the treatment of patients with hepatitis C infection and cirrhosis. Additionally, the paper focuses on the disease burden, epidemiology, diagnosis and the disease course from infection to treatment. We provide an overview of multiple studies for the treatment of chronic hepatitis C infection that have included patients with cirrhosis. We also discuss the advantages and disadvantages of treatment in cirrhotic patients and focus on the most up to date guidelines available for treatment. | Vikas Khullar Roberto J Firpi | 2015 | World Journal of Hepatology2015，7，14： | 3 |
| 3 | Listeria monocytogenes following orthotopic liver transplantation:Central nervous system involvement and review of the literature显示文摘Listeria monocytogene is a well-recognized cause of bacteremia in immunocompromised individuals,including solid organ transplant recipients,but has been rarely reported following orthotopic liver transplantation. We describe a case of listeria meningitis that occurred within a week after liver transplantation. The patient developed a severe headache that mimicked tacrolimus encephalopathy,and was subsequently diagnosed with listeria meningitis by cerebrospinal fluid culture. The infection was successfully treated with three-week course of intravenous ampicillin. Recurrent hepatitis C followed and was successfully treated with interferon alfa and ribavirin. Fourteen cases of listeriosis after orthotopic liver transplantation have been reported in the English literature. Most reported cases were successfully treated with intravenous ampicillin. There were four cases of listeria meningitis,and the mortality of them was 50%. Early detection and treatment of listeria meningitis are the key to obtaining a better prognosis. | Shugo Mizuno Ivan R Zendejas Alan I Reed Robin D Kim Richard J Howard Alan W Hemming Denise C Schain Consuelo Soldevila-Pico Roberto J Firpi Shiro Fujita | 2007 | World Journal of Gastroenterology2007，13，32： | 2 |
| 4 | Lack of antiviral effect of a short course of mycophenolate mofetil in patients with chronic hepatitis C virus infection显示文摘 | Firpi RJ Nelson DR Davis GL | 2003 | Liver-Transpl2003，9，： | 1 |
| 5 | Early hepatic stellate cell aetivation is assoeiated with advanced fibrosis after liver trans- plantation inrecipients with hepatitis C 显示文摘 | Russo MW Firpi IU Nelson DR | 2005 | Liver Transpl2005，11，： | 1 |
| 6 | The natural history of hepatitis C cirrhosis after liver transplantation 显示文摘 | Firpi RJ Clark V Soldevila-Pico C | 2009 | Liver Transpl2009，15，9： | 1 |
| 7 | Short Recovery Time After Percutaneous Liver Biopsy: Should We Change Our Current Practices?显示文摘 | Roberto J. Firpi Consuelo Soldevila–Pico Manal F. Abdelmalek Giuseppe Morelli Joel Judah David R. Nelson | 2005 | Clinical Gastroenterology and Hepatology2005，，9： | 1 |
| 8 | Lack of antiviral effect of a short course of mycophenolate mofetil in patients with chronic hepatitis C virus infection显示文摘 | Firpi R J Nelson DR Davis GL | 2003 | Liver Transpl2003，9，1： | 1 |
| 9 | Treatment outcomes and prognostic factors of intrahepatic cholangiocarcinoma显示文摘 | Renumathy Dhanasekaran Alan Hemming Ivan Zendejas Thomas George David Nelson Consuelo Soldevila-Pico Roberto Firpi Giuseppe Morelli Virginia Clark Roniel Cabrera | 2013 | Oncology Reports2013，，4： | 1 |
| 10 | Viral hepatitis : manifestations and management 显示文摘 | Firpi Roberto J Nelson | 2006 | Strategy Hematol2006，2006，： | 1 |
| 11 | Swarmed feature selection 显示文摘 | Firpi H Goodman E | | Proceedings of 33rd Applied Imagery Pattern Recognition Workshop0，2004，： | 1 |
| 12 | The natural history of hepatitis C cirrhosis after liver transplantation显示文摘 | Firpi RJ Clark V Soldevila-Pico C | 2009 | Liver Transpl2009，15，9： | 1 |
| 13 | Earlyhepatic stellate cell activation is associated with ad-vanced fibrosis after liver transplantation in recipientswith hepatitis 显示文摘 | RUSSO M W FIRPI R J NELSON D R | 2005 | Liver Transpl2005，11，： | 1 |
| 14 | Workpiece dynamic analysis and prediction during chatter of turning process显示文摘 | Cardi A A Firpi H A Bement M T | 2008 | Mechanical Systems and Signal Processing2008，22，6： | 1 |
| 15 | An immunomodulatory role for CD4+CD25+ regulatory T lymphocytes in hepatitis C virus infection显示文摘 | Cabrera R Firpi RJ | 2004 | Hepatology2004，40，5： | 1 |
| 16 | Viral hepatitis:manifestations and management strategy显示文摘 | FIRPI R J NELSON D R | 2006 | Hematol Am Soc Hematol Educ Program2006，，： | 1 |
| 17 | The natural histo- ry of hepatitis C cirrhosis after liver transplantation显示文摘 | Firpi R J Clark V Soldevila - Pico C | 2009 | Liver Transpl2009，15，9： | 1 |
| 18 | Workpiece dynamic analysis and prediction during chatter of turning process 显示文摘 | Cardi A A Firpi H A Bement M T Liang S Y | 2008 | Mechanical Systems and Signal Processing2008，22，6： | 1 |
| 19 | Challenges of recurrent hepatitis C in the liver transplant patient显示文摘Cirrhosis secondary to hepatitis C virus(HCV)is a very common indication for liver transplant.Unfortunately recurrence of HCV is almost universal in patients who are viremic at the time of transplant.The progression of fibrosis has been shown to be more rapid in the post-transplant patients than in the transplant na?ve,hence treatment of recurrent HCV needs to be considered for all patients with documented recurrent HCV.Management of recurrent HCV is a challenging situation both for patients and physicians due to multiple reasons as discussed in this review.The standard HCV treatment with pegylated interferon and Ribavarin can be considered in these patients but it leads to a lower rate of sustained virologic clearance than in the nontransplanted population.Some of the main challenges associated with treating recurrent HCV in post-transplant patients include the presence of cytopenias;need to monitor drug-drug interactions and the increased incidence of renal compromise.In spite of these obstacles all patients with recurrent HCV should be considered for treatment since it is associated with improve-ment in survival and a delay in fibrosis progression.With the arrival of direct acting antiviral drugs there is renewed hope for better outcomes in the treatment of post-transplant HCV recurrence.This review evaluates current literature on this topic and identifies challenges associated with the management of post-transplant HCV recurrence. | Renumathy Dhanasekaran Roberto J Firpi | 2014 | World Journal of Gastroenterology2014，20，13： | 1 |
| 20 | The natural history of hepatitis C cirrhosis after liver transplantation 显示文摘 | Firpi RJ Clark V Soldevila -Pico C | 2009 | Liver Transpl2009，15，9： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员